Hope for Breast Cancer Patients



   For victims of breast cancer, the leading cause of cancer death among women worldwide, Comprehensive Blood and Cancer Center is offering a new hope. Following a four year clinical trial at CBCC, Pablociclib, a breakthrough pharmaceutical by Pfizer, is providing that hope.
   Pablociclib works by specifically targeting the CDK 4 and CDK 6 kinases. By suppressing the CDK 4 and CDK 6 kinases, two closely related enzymes that enable tumor cell progression, tumor cells are prevented from developing during the S-phase of the cell cycle, the cycle in which DNA replication occurs.
   According to CBCC director Ravi Patel, MD, Pablociclib has shown a “significant improvement in what is called survival.” CBCC’s four year trial, which tested eleven patients, has proven a success. One of the patients, at age 78, is “happy, healthy and, once again, regularly playing golf.”
   Pablociclib has received the Federal Food and Drug…

View original post 106 more words


Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s